220 related articles for article (PubMed ID: 29067644)
1. Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
van Erp AEM; Hillebrandt-Roeffen MHS; van Houdt L; Fleuren EDG; van der Graaf WTA; Versleijen-Jonkers YMH
Target Oncol; 2017 Dec; 12(6):815-826. PubMed ID: 29067644
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status.
Dolgikh N; Fulda S
Anticancer Drugs; 2017 Nov; 28(10):1118-1125. PubMed ID: 29045271
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
[TBL] [Abstract][Full Text] [Related]
5. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
[TBL] [Abstract][Full Text] [Related]
6. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
[TBL] [Abstract][Full Text] [Related]
7. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
Cho BC; Kim DW; Bearz A; Laurie SA; McKeage M; Borra G; Park K; Kim SW; Ghosn M; Ardizzoni A; Maiello E; Greystoke A; Yu R; Osborne K; Gu W; Scott JW; Passos VQ; Lau YY; Wrona A
J Thorac Oncol; 2017 Sep; 12(9):1357-1367. PubMed ID: 28729021
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib.
De Pas T; Pala L; Catania C; Conforti F
Future Oncol; 2017 Dec; 13(29):2629-2644. PubMed ID: 28891712
[TBL] [Abstract][Full Text] [Related]
9. Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.
Kang CH; Kim EY; Kim HR; Lee CO; Lee HK; Jeong HG; Choi SU; Yun CS; Hwang JY; Lee JY; Son YH; Ahn S; Lee BH; Jung H; Park CH
Cancer Lett; 2016 May; 374(2):272-8. PubMed ID: 26923554
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
11. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
[TBL] [Abstract][Full Text] [Related]
13. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Landi L; Cappuzzo F
Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
[TBL] [Abstract][Full Text] [Related]
14. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
Vansteenkiste JF
Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer.
Kaczmar J; Mehra R
Ther Adv Respir Dis; 2015 Oct; 9(5):236-41. PubMed ID: 26229087
[TBL] [Abstract][Full Text] [Related]
16. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Miyawaki M; Yasuda H; Tani T; Hamamoto J; Arai D; Ishioka K; Ohgino K; Nukaga S; Hirano T; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Res; 2017 Jan; 15(1):106-114. PubMed ID: 27707887
[TBL] [Abstract][Full Text] [Related]
17. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
18. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
19. Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.
Muller IB; De Langen AJ; Honeywell RJ; Giovannetti E; Peters GJ
Expert Rev Anticancer Ther; 2016; 16(2):147-57. PubMed ID: 26654422
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
van Gaal JC; Flucke UE; Roeffen MH; de Bont ES; Sleijfer S; Mavinkurve-Groothuis AM; Suurmeijer AJ; van der Graaf WT; Versleijen-Jonkers YM
J Clin Oncol; 2012 Jan; 30(3):308-15. PubMed ID: 22184391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
